Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,004Revenue $M42.1Net Margin (%)-191.1Z-Score-3.7
Enterprise Value $M970EPS $-0.7Operating Margin %-169.9F-Score2
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-191.1Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %-8.3Quick Ratio2.2Cash flow > EarningsY
Price/Sales19.95-y EBITDA Growth Rate %-28.2Current Ratio2.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-62.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M140ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ARRY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARRYJean-Marie Eveillard 2011-12-31 Sold Out -0.0024%$1.77 - $2.83
($2.28)
$ 7.1968%Sold Out0
ARRYGeorge Soros 2011-12-31 Sold Out -0.0008%$1.77 - $2.83
($2.28)
$ 7.1968%Sold Out0
ARRYGeorge Soros 2011-09-30 Buy $1.99 - $2.62
($2.24)
$ 7.1969%New holding22,400
ARRYJean-Marie Eveillard 2011-06-30 Add$2.06 - $3.21
($2.7)
$ 7.1962%Add 150.00%250,000
ARRYGeorge Soros 2011-06-30 Sold Out $2.06 - $3.21
($2.7)
$ 7.1962%Sold Out0
ARRYJean-Marie Eveillard 2011-03-31 Buy $2.7 - $3.29
($3)
$ 7.1958%New holding100,000
ARRYGeorge Soros 2011-03-31 Buy $2.7 - $3.29
($3)
$ 7.1958%New holding14,400
ARRYJean-Marie Eveillard 2010-09-30 Sold Out -0.01%$2.67 - $3.44
($3.02)
$ 7.1958%Sold Out0
ARRYJean-Marie Eveillard 2010-06-30 Reduce-0.01%$2.66 - $4.02
($3.41)
$ 7.1953%Reduce -54.96%450,000
ARRYJean-Marie Eveillard 2009-12-31 Add0.01%$1.72 - $2.81
($2.2)
$ 7.1969%Add 62.96%999,132
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARRY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARRY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LEFKOFF KYLEDirector 2015-03-03Sell70,000$8-10.13 view
Squarer RonCEO 2015-03-02Sell40,000$8.25-12.85 view
Robbins Andrews RSVP, Commercial Operations 2015-03-02Sell21,576$8.25-12.85 view
BVF PARTNERS L P/IL10% Owner 2014-06-25Sell0$0-12.85 view
MOORE JOHN RVP, General Counsel 2013-11-29Sell11,666$5.7924.18 view
MOORE JOHN RVP, General Counsel 2013-11-13Sell200$5.7924.18 view
Ratcliffe LiamDirector 2013-09-27Sell1,125,728$619.83 view
Ratcliffe LiamDirector 2013-09-16Sell1,673,172$6.0818.26 view
Ratcliffe LiamDirector 2013-09-06Sell577,286$5.7924.18 view
MOORE JOHN RVP, General Counsel 2013-08-02Sell75,384$7.022.42 view

Press Releases about ARRY :

    Quarterly/Annual Reports about ARRY:

    News about ARRY:

    Articles On GuruFocus.com
    Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    comment on ARRY Mar 02 2013 
    Re: ARRY Aug 29 2011 
    Drug Penny Stock Aug 23 2011 
    Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
    Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
    Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
    Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
    Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 

    More From Other Websites
    Biotech Investors: May 29th Could Be A Big Day Apr 21 2015
    Array BioPharma CEO Sees Big Opportunities in the Future Mar 31 2015
    Array BioPharma CEO: Novartis Deal a Massive Momentum Builder Mar 31 2015
    The latest drugs being tested to fight melanoma Mar 30 2015
    ARRAY BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Mar 02 2015
    Array Announces Completion Of Binimetinib And Encorafenib Transactions Mar 02 2015
    Array BioPharma draws bullish bet Feb 26 2015
    Array BioPharma To Present At The Cowen and Company Annual Healthcare Conference Feb 25 2015
    How To Approach Momentum Trading Like A Pro Feb 18 2015
    ARRAY BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 13 2015
    ARRAY BIOPHARMA INC Financials Feb 11 2015
    Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog Feb 10 2015
    10-Q for Array BioPharma, Inc. Feb 07 2015
    Array BioPharma To Present At The Leerink Swann Global Healthcare Conference Feb 05 2015
    Array BioPharma To Present At The Leerink Swann Global Healthcare Conference Feb 05 2015
    ARRAY BIOPHARMA INC Files SEC form 10-Q, Quarterly Report Feb 04 2015
    Array BioPharma reports 2Q loss Feb 03 2015
    Array BioPharma reports 2Q loss Feb 03 2015
    Array Biopharma Inc Earnings Call scheduled for 9:00 am ET today Feb 03 2015
    ARRAY BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Feb 03 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK